All In Biotech

Drug Trial Radar · NCT02472795

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jun 1, 2015

Primary completion

Jan 23, 2017

Study completion Feb 28, 2017

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Jun 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Matching placeboDrug

    One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

  • CenerimodDrug

    One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)Time frame: Baseline to end-of-treatment (EOT) (up to 12 weeks)
  2. Change in Total Lymphocyte Count From Baseline to Each Post-baseline AssessmentTime frame: Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Anniston, Alabama

  • Investigator Site

    Clearwater, Florida

  • Investigator Site

    Minsk, Belarus

  • Investigator Site

    Minsk, Belarus

  • Investigator Site

    Vitebsk, Belarus

  • Investigator Site

    Plovdiv, Bulgaria

  • Investigator Site

    Plovdiv, Bulgaria

  • Investigator Site

    Sofia, Bulgaria

  • Investigator Site

    Tbilisi, Georgia

  • Investigator Site

    Kemerovo, Russia

  • Investigator Site

    Kursk, Russia

  • Investigator Site

    Omsk, Russia

  • Investigator Site

    Orenburg, Russia

  • Investigator Site

    Smolensk, Russia

  • Investigator Site

    Vladimir, Russia

  • Investigator Site

    Vinnytsia, Ukraine

  • Investigator Site

    Vinnytsia, Ukraine

  • Investigator Site

    Zaporizhia, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.